179 related articles for article (PubMed ID: 24919974)
1. Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year.
Al-Khadra S; Meisinger C; Amann U; Holle R; Kuch B; Seidl H; Kirchberger I
Drugs Aging; 2014 Jul; 31(7):513-25. PubMed ID: 24919974
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
3. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
[TBL] [Abstract][Full Text] [Related]
4. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
[TBL] [Abstract][Full Text] [Related]
5. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
[TBL] [Abstract][Full Text] [Related]
6. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
[TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
[TBL] [Abstract][Full Text] [Related]
8. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
[TBL] [Abstract][Full Text] [Related]
9. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
10. Determinants of Insufficient Optimal Medical Therapy after Acute Myocardial Infarction.
Haraguchi Y; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
Intern Med; 2020 Jun; 59(12):1489-1495. PubMed ID: 32188806
[TBL] [Abstract][Full Text] [Related]
11. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
[TBL] [Abstract][Full Text] [Related]
12. [Organisational determinants of adherence to secondary prevention medications after acute myocardial infarction].
Perrone E; Lenzi J; Avaldi VM; Castaldini I; Protonotari A; Rucci P; Piccinni C; Morini M; Fantini MP
Epidemiol Prev; 2015; 39(2):106-14. PubMed ID: 26036739
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
14. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
[TBL] [Abstract][Full Text] [Related]
15. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
[TBL] [Abstract][Full Text] [Related]
16. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
[TBL] [Abstract][Full Text] [Related]
17. Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case-control study.
Lenzi J; Rucci P; Castaldini I; Protonotari A; Di Pasquale G; Di Martino M; Perrone E; Forti P; Fantini MP
Eur J Clin Pharmacol; 2015 Feb; 71(2):243-50. PubMed ID: 25529226
[TBL] [Abstract][Full Text] [Related]
18. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Hudson M; Richard H; Pilote L
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
[TBL] [Abstract][Full Text] [Related]
19. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
20. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
